Roman Dvorak

Company: Lipidio Pharmaceuticals

Job title: Chief Medical Officer

Seminars:

Targeting Obesity Through Skin-Based SCD-1 Inhibition: The Potential of GDD3898 2:15 pm

Exploring GDD3898, Lipidio’s novel compound, works by inhibiting SCD-1 specifically in the skin, offering a novel approach to treating obesity through localized mechanisms that impact systemic metabolism Exploring the reduction in fat storage and enhancement of energy expenditure by targeting SCD-1, detailing a new class of therapeutic that act through the skin rather than traditional…Read more

day: Conference Day Two